Abstract Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is characterized by non-cardiogenic, acute and progressive respiratory failure mediated by a variety of injurious stimuli. ALI can progress to ARDS if an effective management is not taken. The mortality rate remains high due to the complex pathogenesis and ineffective management of ARDS. At present, effective treatment methods for ALI are not available and thus it is important to study the pathogenesis and early diagnosis of ALI. This article reviews some of the biomarkers associated with ALI, with a focus on early diagnosis and future studies.
Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment[J]. Annu Rev Pathol, 2011, 6: 147-163.
[2]
Cross LJ, Matthay MA. Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury[J]. Crit Care Clin, 2011, 27(2): 355-377.
[3]
Hu X, Qian S, Xu F, et al. Incidence, management and mortality of acute hypoxemic respiratory failure and acute respiratory distress syndrome from a prospective study of Chinese Paediatric Intensive Care Network[J]. Acta Paediatr, 2010, 99(5): 715-721.
[4]
Mcclintock D, Zhuo H, Wickersham N, et al. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury[J]. Crit Care, 2008, 12(2): R41.
[5]
Uchida T, Shirasawa M, Ware LB. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury[J]. Am J Respir Crit Care Med, 2006, 173(9): 1008-1015.
[6]
Fineschi S, De Cunto G, Facchinetti F, et al. Receptor for advanced glycation end products contributes to postnatal pulmonary development and adult lung maintenance program in mice[J]. Am J Respir Cell Mol Biol, 2013, 48(2):164-171.
[7]
Zhang H, Tasaka S, Shiraishi Y, et al. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury[J].Am J Respir Crit Care Med, 2008, 178(4): 356-362.
[8]
Christaki E, Opal SM, Keith JJ, et al. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia[J]. Shock, 2011, 35(5): 492-498.
[9]
Silveyra P, Floros J. Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury[J]. Front Biosci, 2012, 17: 407-429.
[10]
Mosbah AA, Abdellatif NA, Sorour EI, et al. Serum SP-D levels as a biomarker of lung injury in children suffering of bronchopneumonia[J]. J Egypt Soc Parasitol, 2012, 42(1): 25-32.
[11]
Clark HW. Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease?[J]. Neonatology, 2010, 97(4): 380-387.
[12]
Kondo T, Hattori N, Ishikawa N, et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome[J]. Respir Res, 2011, 12: 32.
[13]
Determann RM, Royakkers AA, Haitsma JJ, et al. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients[J]. BMC Pulm Med, 2010, 10: 6.
[14]
Abdel-Latif ME, Osborn DA. Intratracheal Clara cell secretory protein (CCSP) administration in preterm infants with or at risk of respiratory distress syndrome[J]. Cochrane Database Syst Rev, 2011(5): D8308.
[15]
Kropski JA, Fremont RD, Calfee CS. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury[J]. Chest, 2009, 135(6): 1440-1447.
[16]
Determann RM, Millo JL, Waddy S, et al. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study[J]. BMC Pulm Med, 2009, 9:49.
[17]
Menoret A, Kumar S, Vella AT. Cytochrome b5 and cytokeratin 17 are biomarkers in bronchoalveolar fluid signifying onset of acute lung injury[J]. PLoS One, 2012, 7(7): e40184.
[18]
Katayama M, Ishizaka A, Sakamoto M, et al. Laminin gamma2 fragments are increased in the circulation of patients with early phase acute lung injury[J]. Intensive Care Med, 2010, 36(3): 479-486.
[19]
Urich D, Eisenberg JL, Hamill KJ, et al. Lung-specific loss of the laminin alpha3 subunit confers resistance to mechanical injury[J]. J Cell Sci, 2011, 124(Pt 17): 2927-2937.
[20]
Mcclintock DE, Starcher B, Eisner MD, et al. Higher urine desmosine levels are associated with mortality in patients with acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2006, 291(4): L566-L571.
[21]
Goodman RB, Pugin J, Lee JS, et al. Cytokine-mediated inflammation in acute lung injury[J]. Cytokine Growth Factor Rev, 2003, 14(6): 523-535.
[22]
Yang G, Hamacher J, Gorshkov B, et al. The dual role of TNF in pulmonary edema[J]. J Cardiovasc Dis Res, 2010, 1(1): 29-36.
[23]
Bhargava M, Wendt CH. Biomarkers in acute lung injury[J]. Transl Res, 2012, 159(4): 205-217.
[24]
Quesnel C, Marchand-Adam S, Fabre A, et al. Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2008, 294(2): L334-L343.
[25]
Lin WC, Lin CF, Chen CL, et al. Prediction of outcome in patients with acute respiratory distress syndrome by bronchoalveolar lavage inflammatory mediators[J]. Exp Biol Med (Maywood), 2010, 235(1): 57-65.
[26]
Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury[J]. Crit Care Med, 2005, 33(1): 1-6, 230-232.
[27]
Lindsay CD. Novel therapeutic strategies for acute lung injury induced by lung damaging agents: the potential role of growth factors as treatment options[J]. Hum Exp Toxicol, 2011, 30(7): 701-724.
[28]
Li X, Li S, Zhang M, et al. Protective effects of a bacterially expressed NIF-KGF fusion protein against bleomycin-induced acute lung injury in mice[J]. Acta Biochim Biophys Sin (Shanghai), 2010, 42(8): 548-557.
Yee M, White RJ, Awad HA, et al. Neonatal hyperoxia causes pulmonary vascular disease and shortens life span in aging mice[J]. Am J Pathol, 2011, 178(6): 2601-2610.
[31]
Wada T, Jesmin S, Gando S, et al. The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness[J]. J Inflamm (Lond), 2013, 10(1): 6.
[32]
Gonzalez-Lopez A, Albaiceta GM. Repair after acute lung injury: molecular mechanisms and therapeutic opportunities[J]. Crit Care, 2012, 16(2): 209.
[33]
Barnett N, Ware LB. Biomarkers in acute lung injury-marking forward progress[J]. Crit Care Clin, 2011, 27(3): 661-683.
[34]
Sapru A, Curley MA, Brady S, et al. Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury[J]. Intensive Care Med, 2010, 36(1): 157-163.
[35]
Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury[J]. Chest, 2010, 137(2): 288-296.
